Clevudine: Difference between revisions
(Created page with "<div style="float: right;"> thumb|none|400px|This image is provided by the National Library of Medicine.</div> __NOTOC__ {{SI}} {{CMG}} ==Overview==...") |
m (Protected "Clevudine": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
<div style="float: right;"> | <div style="float: right;"> | ||
[[File:Clevudine.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]</div> | [[File:Clevudine.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]</div> | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
'''Clevudine''' ([[International Nonproprietary Name|INN]]) is an antiviral drug for the treatment of [[hepatitis B]] (HBV). It is already approved for HBV in [[South Korea]] and the [[Philippines]]. It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames '''Levovir''' and '''Revovir'''. | '''Clevudine''' ([[International Nonproprietary Name|INN]]) is an antiviral drug for the treatment of [[hepatitis B]] (HBV). It is already approved for HBV in [[South Korea]] and the [[Philippines]]. It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames '''Levovir''' and '''Revovir'''. | ||
| Line 17: | Line 13: | ||
{{Antivirals}} | {{Antivirals}} | ||
[[Category:Organofluorides]] | [[Category:Organofluorides]] | ||
[[Category:Drug]] | [[Category:Drug]] | ||
Latest revision as of 19:12, 18 August 2015
|
WikiDoc Resources for Clevudine |
|
Articles |
|---|
|
Most recent articles on Clevudine |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Clevudine at Clinical Trials.gov Clinical Trials on Clevudine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Clevudine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Clevudine Discussion groups on Clevudine Directions to Hospitals Treating Clevudine Risk calculators and risk factors for Clevudine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Clevudine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Clevudine (INN) is an antiviral drug for the treatment of hepatitis B (HBV). It is already approved for HBV in South Korea and the Philippines. It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames Levovir and Revovir.
Under license from Bukwang, Pharmasset was developing the drug, but its phase III clinical trial (international, multicenter, randomized, double-blind, 96 week QUASH studies) was terminated due to some myopathy cases in patients. It's approval in South Korea was revoked following these findings. It is a nucleoside analog.